Abzena & Regeneron’s Journal Article on Potent Rifampicin Derivatives

Abzena & Regeneron published a recent scientific journal article entitled,  “Potent Rifampicin derivatives can clear MRSA infections at single low doses when concomitantly dosed with Vancomycin”.

Click Here to Access the Journal Publication

Journal Abstract
For a number of years, antimicrobial resistance (AMR) has been a critical issue for humanity. Drug discovery efforts have been very limited and the spread of bacterial pathogens has over-run our traditional arsenal of antibiotics. Bacteria can involve to evade compounds that can halt their rapid growth. The authors have discovered a potent macrocycle derivative that when dosed concomitantly with the standard of care (SOC) antibiotic vancomycin, can clear methicillin resistant Staphylococcus aureus (MRSA) infections. In addition, we have probed the lead compounds in Salmonella Typhimurium bacterial strains. In vitro, in vivo, and ADME data have been included to stress the virtues of this new antibiotic.

Solutions for improving early phase development

Abzena offers comprehensive bioassay solutions including both established assays and custom assay development matched to your individual program needs. Our approach focuses on developing phase-appropriate assays for the assessment of potency, efficacy, and safety, giving you tools and the data to drive effective decision-making during your drug development journey to IND and beyond.  In discovery, we provide target validation support with in vitro gene/protein expression, functional analysis, and biomarker profiling.  We also aid in identifying lead candidates to move forward into development by assessing functional activity and target binding and affinity utilizing ELISA, Biocore, and flow cytometry. When it comes time to design and develop your molecule, we assist in specificity and tissue profiling and mode of action (MoA) support with PK & PD assessments, cytokine analysis, Fc effector function, and Immunogenicity. When your program is ready for manufacture, our team can support your program by developing ELISA or cell-based binding assays, and MoA-reflective potency assays. Our extensive scientific capabilities and innovative solutions are designed to reduce risk and give your program the best chance of clinical and commercial success.

For more information about Abzena’s extensive bioassay capabilities visit: Functional Activity & Immunogenicity — abzena

The post Abzena & Regeneron’s Journal Article on Potent Rifampicin Derivatives appeared first on abzena.